Advertisement

Rescue of Narcoleptic Orexin Neuron-Ablated Mice by Ectopic Overexpression of Orexin Peptides

  • Michihiro Mieda
  • Jon T. Willie
  • Takeshi Sakurai
Part of the Contemporary Clinical Neuroscience book series (CCNE)

Abstract

Human narcolepsy-cataplexy is a debilitating neurological disease characterized by excessive daytime sleepiness, premature transitions to REM sleep (called sleep-onset REM periods), and cataplexy (sudden bilateral skeletal muscle weakness without impairment of consciousness). Narcolepsy-cataplexy affects males and females equally, with an estimated prevalence of 0.02–0.18% within white populations. Most cases of narcolepsy-cataplexy are idiopathic, and symptoms appear around adolescence and last throughout life. Several studies have reported a strong association between certain class II HLA haplotypes on human chromosome 6 and narcolepsy-cataplexy; HLA DQB1*0602 and DQA1*0102 are found in up to 90% of affected populations, compared with 12–38% in the general population, suggesting that autoimmunity plays a role in the disorder. Excessive sleepiness is treated using psychostimulants, such as amphetamines, and modafinil; cataplexy is treated with tricyclic antidepressants such as clomipramine. However, this therapeutic regimen is problematic owing to limited effectiveness, undesirable side effects such as insomnia or symptom rebounds, and the potential for abuse (1,2).

Keywords

Double Transgenic Mouse Orexin Neuron Orexin Receptor Genetic Rescue Human Narcolepsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mignot, E., Lammers, G.J., Ripley, B., et al. (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553–1562.PubMedCrossRefGoogle Scholar
  2. 2.
    Scammell, T.E. (2003) The neurobiology, diagnosis, and treatment of narcolepsy. Ann. Neurol. 53, 154–166.PubMedCrossRefGoogle Scholar
  3. 3.
    Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., and Mignot, E. (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Lin, L., Faraco, J., Li, R., et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365–376.PubMedCrossRefGoogle Scholar
  5. 5.
    Peyron, C., Faraco, J., Rogers, W., et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991–997.PubMedCrossRefGoogle Scholar
  6. 6.
    Chemelli, R.M., Willie, J.T., Sinton, C.M., et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437–451.PubMedCrossRefGoogle Scholar
  7. 7.
    Thannickal, T.C., Moore, R.Y., Nienhuis, R., et al. (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469–474.PubMedCrossRefGoogle Scholar
  8. 8.
    Hara, J., Beuckmann, C.T., Nambu, T., et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345–354.PubMedCrossRefGoogle Scholar
  9. 9.
    Sakurai, T., Amemiya, A., Ishii, M., et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585.PubMedCrossRefGoogle Scholar
  10. 10.
    Peyron, C., Tighe, D.K., van den Pol, A.N., et al. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996–10,015.PubMedGoogle Scholar
  11. 11.
    Piper, D.C., Upton, N., Smith, M.I., and Hunter, A.J. (2000) The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. 12, 726–730.PubMedCrossRefGoogle Scholar
  12. 12.
    Huang, Z.L., Qu, W.M., Li, W.D., et al. (2001) Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U S A 98, 9965–9970.PubMedCrossRefGoogle Scholar
  13. 13.
    Willie, J.T., Chemelli, R.M., Sinton, C.M., et al. (2003) Distinct narcolepsy syndromes in orexin receptor 2 (OX2R) and orexin knockout mice: OX2R selectively maintains wakefulness and prevents attacks of non-rapid eye movement sleep. Neuron 38, 715–730.PubMedCrossRefGoogle Scholar
  14. 14.
    Willie, J.T., Chemelli, R.M., Sinton, C.M., and Yanagisawa, M. (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24, 429–458.PubMedCrossRefGoogle Scholar
  15. 15.
    van den Pol, A.N. (2000) Narcolepsy: a neurodegenerative disease of the hypocretin system? Neuron 27, 415–418.PubMedCrossRefGoogle Scholar
  16. 16.
    Mieda, M., Willie, J.T., Hara, J., Sinton, C.M., Sakurai, T., and Yanagisawa, M. (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. U S A 101, 4649–4654.PubMedCrossRefGoogle Scholar
  17. 17.
    Niwa, H. Yamamura, K., and Miyazaki, J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193–199.PubMedCrossRefGoogle Scholar
  18. 18.
    Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., and Nishino, S. (2003) Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26, 953–959.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Michihiro Mieda
    • 1
  • Jon T. Willie
    • 2
  • Takeshi Sakurai
    • 3
    • 4
  1. 1.Department of Molecular Neuroscience, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Departments of Molecular Genetics and Howard Hughes Medical InstituteUniversity of Texas Southwestern Medical CenterDallas
  3. 3.Department of Pharmacology, Institute of Basic Medical SciencesUniversity of TsukubaIbarakiJapan
  4. 4.ERATO Yanagisawa Orphan Receptor ProjectJapan Science and Technology AgencyTokyoJapan

Personalised recommendations